Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre

Aneel Arjun Ashrani, J. Osip, B. Christie, N. S. Key

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Iliopsoas haemorrhage in patients with bleeding disorders is a potentially life-threatening condition, with significantly associated morbidity. Despite its clinical importance, little has been published on the frequency, complications or outcomes of this entity since the advent of modern therapies for haemophilia. In a retrospective review of 297 patients with bleeding disorders followed at our centre, we identified 46 episodes of iliopsoas haemorrhage in 31 patients. Patients presented primarily with thigh, hip and/or groin pain, and frequently had flexion hip contracture, femoral nerve paresthesia, and >2 g dL-1 haemoglobin drop. The duration of symptoms prior to seeking medical attention was 3.8 ± 4 days. Nineteen of 155 patients (12.3%) with haemophilia A had 28 episodes of iliopsoas bleed; 52.6% of these patients had severe haemophilia. Of these 19 patients with haemophilia A who had iliopsoas haemorrhage, seven (36.8%) had an inhibitor to factor VIII (FVIII), and accounted for one-half of the bleeding episodes. Nine of 66 patients (13.6%) with haemophilia B had 15 episodes of iliopsoas haemorrhage; 22.2% of these patients had severe haemophilia, including one patient with an inhibitor to FIX who had two iliopsoas bleeds. The mean duration of therapy was 18.7 ± 11.9 days, and the duration of hospitalization was 12.3 ± 9.1 days. The length of hospital stay was significantly longer in patients with inhibitors, when compared with patients without inhibitors (19.1 ± 5.8 days vs. 7.6 ± 7.8 days; P < 0.0001) with higher factor consumption, although the total duration of therapy was not significantly different. Patients with inhibitors were over-represented in the cohort of haemophiliacs with iliopsoas bleed. Patients with inhibitors who had iliopsoas bleeds remained hospitalized longer, although the duration of therapy was the same as patients with no inhibitors. There was a low frequency of recurrent bleed (2.8%).

Original languageEnglish (US)
Pages (from-to)721-726
Number of pages6
JournalHaemophilia
Volume9
Issue number6
StatePublished - Nov 2003
Externally publishedYes

Fingerprint

Hemorrhage
Hemophilia A
Length of Stay
Hip Contracture
Femoral Nerve
Hemophilia B
Groin
Paresthesia
Factor VIII
Therapeutics
Thigh
Hip
Hemoglobins
Hospitalization
Morbidity
Pain

Keywords

  • Bleeding disorders/complications
  • Haematoma/ aetiology
  • Haemophilia/complications
  • Iliopsoas muscle
  • Treatment outcome

ASJC Scopus subject areas

  • Hematology

Cite this

Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre. / Ashrani, Aneel Arjun; Osip, J.; Christie, B.; Key, N. S.

In: Haemophilia, Vol. 9, No. 6, 11.2003, p. 721-726.

Research output: Contribution to journalArticle

Ashrani, AA, Osip, J, Christie, B & Key, NS 2003, 'Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre', Haemophilia, vol. 9, no. 6, pp. 721-726.
Ashrani, Aneel Arjun ; Osip, J. ; Christie, B. ; Key, N. S. / Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre. In: Haemophilia. 2003 ; Vol. 9, No. 6. pp. 721-726.
@article{dce8daa8087f4351af2b62c5712b50a3,
title = "Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre",
abstract = "Iliopsoas haemorrhage in patients with bleeding disorders is a potentially life-threatening condition, with significantly associated morbidity. Despite its clinical importance, little has been published on the frequency, complications or outcomes of this entity since the advent of modern therapies for haemophilia. In a retrospective review of 297 patients with bleeding disorders followed at our centre, we identified 46 episodes of iliopsoas haemorrhage in 31 patients. Patients presented primarily with thigh, hip and/or groin pain, and frequently had flexion hip contracture, femoral nerve paresthesia, and >2 g dL-1 haemoglobin drop. The duration of symptoms prior to seeking medical attention was 3.8 ± 4 days. Nineteen of 155 patients (12.3{\%}) with haemophilia A had 28 episodes of iliopsoas bleed; 52.6{\%} of these patients had severe haemophilia. Of these 19 patients with haemophilia A who had iliopsoas haemorrhage, seven (36.8{\%}) had an inhibitor to factor VIII (FVIII), and accounted for one-half of the bleeding episodes. Nine of 66 patients (13.6{\%}) with haemophilia B had 15 episodes of iliopsoas haemorrhage; 22.2{\%} of these patients had severe haemophilia, including one patient with an inhibitor to FIX who had two iliopsoas bleeds. The mean duration of therapy was 18.7 ± 11.9 days, and the duration of hospitalization was 12.3 ± 9.1 days. The length of hospital stay was significantly longer in patients with inhibitors, when compared with patients without inhibitors (19.1 ± 5.8 days vs. 7.6 ± 7.8 days; P < 0.0001) with higher factor consumption, although the total duration of therapy was not significantly different. Patients with inhibitors were over-represented in the cohort of haemophiliacs with iliopsoas bleed. Patients with inhibitors who had iliopsoas bleeds remained hospitalized longer, although the duration of therapy was the same as patients with no inhibitors. There was a low frequency of recurrent bleed (2.8{\%}).",
keywords = "Bleeding disorders/complications, Haematoma/ aetiology, Haemophilia/complications, Iliopsoas muscle, Treatment outcome",
author = "Ashrani, {Aneel Arjun} and J. Osip and B. Christie and Key, {N. S.}",
year = "2003",
month = "11",
language = "English (US)",
volume = "9",
pages = "721--726",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Iliopsoas haemorrhage in patients with bleeding disorders - Experience from one centre

AU - Ashrani, Aneel Arjun

AU - Osip, J.

AU - Christie, B.

AU - Key, N. S.

PY - 2003/11

Y1 - 2003/11

N2 - Iliopsoas haemorrhage in patients with bleeding disorders is a potentially life-threatening condition, with significantly associated morbidity. Despite its clinical importance, little has been published on the frequency, complications or outcomes of this entity since the advent of modern therapies for haemophilia. In a retrospective review of 297 patients with bleeding disorders followed at our centre, we identified 46 episodes of iliopsoas haemorrhage in 31 patients. Patients presented primarily with thigh, hip and/or groin pain, and frequently had flexion hip contracture, femoral nerve paresthesia, and >2 g dL-1 haemoglobin drop. The duration of symptoms prior to seeking medical attention was 3.8 ± 4 days. Nineteen of 155 patients (12.3%) with haemophilia A had 28 episodes of iliopsoas bleed; 52.6% of these patients had severe haemophilia. Of these 19 patients with haemophilia A who had iliopsoas haemorrhage, seven (36.8%) had an inhibitor to factor VIII (FVIII), and accounted for one-half of the bleeding episodes. Nine of 66 patients (13.6%) with haemophilia B had 15 episodes of iliopsoas haemorrhage; 22.2% of these patients had severe haemophilia, including one patient with an inhibitor to FIX who had two iliopsoas bleeds. The mean duration of therapy was 18.7 ± 11.9 days, and the duration of hospitalization was 12.3 ± 9.1 days. The length of hospital stay was significantly longer in patients with inhibitors, when compared with patients without inhibitors (19.1 ± 5.8 days vs. 7.6 ± 7.8 days; P < 0.0001) with higher factor consumption, although the total duration of therapy was not significantly different. Patients with inhibitors were over-represented in the cohort of haemophiliacs with iliopsoas bleed. Patients with inhibitors who had iliopsoas bleeds remained hospitalized longer, although the duration of therapy was the same as patients with no inhibitors. There was a low frequency of recurrent bleed (2.8%).

AB - Iliopsoas haemorrhage in patients with bleeding disorders is a potentially life-threatening condition, with significantly associated morbidity. Despite its clinical importance, little has been published on the frequency, complications or outcomes of this entity since the advent of modern therapies for haemophilia. In a retrospective review of 297 patients with bleeding disorders followed at our centre, we identified 46 episodes of iliopsoas haemorrhage in 31 patients. Patients presented primarily with thigh, hip and/or groin pain, and frequently had flexion hip contracture, femoral nerve paresthesia, and >2 g dL-1 haemoglobin drop. The duration of symptoms prior to seeking medical attention was 3.8 ± 4 days. Nineteen of 155 patients (12.3%) with haemophilia A had 28 episodes of iliopsoas bleed; 52.6% of these patients had severe haemophilia. Of these 19 patients with haemophilia A who had iliopsoas haemorrhage, seven (36.8%) had an inhibitor to factor VIII (FVIII), and accounted for one-half of the bleeding episodes. Nine of 66 patients (13.6%) with haemophilia B had 15 episodes of iliopsoas haemorrhage; 22.2% of these patients had severe haemophilia, including one patient with an inhibitor to FIX who had two iliopsoas bleeds. The mean duration of therapy was 18.7 ± 11.9 days, and the duration of hospitalization was 12.3 ± 9.1 days. The length of hospital stay was significantly longer in patients with inhibitors, when compared with patients without inhibitors (19.1 ± 5.8 days vs. 7.6 ± 7.8 days; P < 0.0001) with higher factor consumption, although the total duration of therapy was not significantly different. Patients with inhibitors were over-represented in the cohort of haemophiliacs with iliopsoas bleed. Patients with inhibitors who had iliopsoas bleeds remained hospitalized longer, although the duration of therapy was the same as patients with no inhibitors. There was a low frequency of recurrent bleed (2.8%).

KW - Bleeding disorders/complications

KW - Haematoma/ aetiology

KW - Haemophilia/complications

KW - Iliopsoas muscle

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=0346327465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346327465&partnerID=8YFLogxK

M3 - Article

C2 - 14750939

AN - SCOPUS:0346327465

VL - 9

SP - 721

EP - 726

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

IS - 6

ER -